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most patients but less than 5% of patients achieve a molecular
remission. Therefore, combination regimens consisting of alloge-
neic HSCT and imatinib have been proposed. We used murine
models of allogeneic HSCT to investigate the effects of imatinib
administration in the peri-transplant period. We used an MHC-
matched allogeneic HSCT model (B10.BR 3 CBA) and a con-
genic syngeneic HSCT model (Ly5.1 3 B6). All mice received
lethal doses of radiation followed by injection of 5  106 T-cell
depleted bone marrow cells. Imatinib was administered via intra-
peritoneal injection twice daily from day 1 to day 8 of transplant
at a dose of 45 mg/kg/dose. In the congenic model, all imatinib-
treated mice died by day 8 whereas control mice had 100% survival
(combined data of 2 transplants; n16; p
0.0001). Similarly, the
imatinib-treated mice in the allogeneic HSCT model had inferior
survival compared to controls (p0.0001). We analyzed imatinib-
treated allogeneic HSCT recipients on day 14 and found that
thymocyte counts were signiﬁcantly reduced in the imatinib
treated group (0.96  106) compared to controls (8.2  106)
(p
0.00002). The numbers of CD4, CD8 and double positive
thymocytes were also signiﬁcantly reduced. Total splenocyte
counts were diminished in the imatinib-treated group as well, but
the difference was not signiﬁcant (29.8  106 vs. 37.3  106). The
numbers of splenic CD3 T cells, B220 B cells and NK1.1 NK
cells were signiﬁcantly reduced in the imatinib-treated allogeneic
HSCT recipients. We found no differences in the total number of
bone marrow cells or CFU-GM or BFU-E colonies in imatinib-
treated mice versus controls. We performed weekly complete
blood counts and noted signiﬁcant decreases in the hemoglobin
concentration (day 7 and 14), platelets (day 7) and lympho-
cytes (day 21). In conclusion, peri-transplant administration of
imatinib to recipients of a syngeneic or allogeneic T-cell depleted
HSCT results in signiﬁcant mortality, which is associated with
profound defects in T-, B- and NK-lymphopoiesis, as well as
moderate decreases in erythrocyte and platelet recovery.
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CD4V11 T CELLS EXHIBIT LIMITED TCR- REPERTOIRE DIVER-
SITY IN THE miHA-MATCHED C57BL/6 3 BALB.B MODEL OF GRAFT-
VERSUS-HOST DISEASE
DiRienzo, C.G.; Friedman, T.; Korngold, R. Thomas Jefferson Univer-
sity Kimmel Cancer Center, Philadelphia, PA.
Spectratype analysis of the TCR V chain is a useful tool for
examining the T cell repertoire of clonally expanded populations of
T cells responding to minor histocompatibility antigens (miHAs)
during graft-versus-host disease (GVHD). The nature of miHAs in
the CD4-mediated, H2b-matched C57BL/6 3 BALB.B model
remains elusive, but previous spectratype analysis demonstrated a
vital role for CD4V11 T cells in mediating GVHD. Transfer
of C57BL/6 CD4V11T cells, along with T cell-depleted bone
marrow, caused lethal GVHD in BALB.B mice. The TCR V
chain alone does not determine the speciﬁcity of peptide-MHC
recognition. The speciﬁcity of peptide-MHC recognition is mainly
determined by the CDR1 and CDR3 loops of both the TCR- and
- chains. Evidence from crystallographic studies, TCR- trans-
genic mice, and tumor-reactive T cells from humans showed that
a single TCR- chain could pair with multiple TCR- chains and
still maintain peptide speciﬁcity. These studies suggest that the
TCR- chain may have a predominant role in antigen recognition.
Analysis of the TCR- chain has not been previously examined
using the well-characterized system of spectratype analysis. Upon
transplant of unfractionated C57BL/6 CD4 T cells into lethally
irradiated BALB.B recipients, analysis of the TCR- repertoire
within the BALB.B-reactive CD4V11 C57BL/6 T cell popu-
lation was performed on day 10. Our data show that there is limited
V diversity in the CD4V11 response to BALB.B miHAs. The
limited TCR diversity seen with both the V and V chains
suggests that C57BL/6 CD4 T cells recognize a limited number
of antigenic peptides in this model.
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PURE RED CELL APLASIA (PRCA) FOLLOWING ABO-INCOMPATIBLE
ALLOGENEIC BONE MARROW TRANSPLANTATION
Sethi, S.1,2; Hamadani, M.H.1; Kamble, R.1,2; Kharfan-Dabaja, M.1,2;
Ozer, H.1,2; Selby, G.S.1,2 1. Department of Internal Medicine, Okla-
homa University Health Sciences Center, Oklahoma City, OK; 2. Section
of Hematology and Oncology and Bone Marrow Transplantation, Okla-
homa University Health Sciences Center, Oklahoma City, OK.
Background: Pure red cell aplasia (PRCA) following ABO in-
compatible allogenic BMT has been reported. The treatment of
PRCA varies widely with no clear consensus amongst transplant
institutions. Method: 3 patients were found to have PRCA. Ret-
rospective analysis of patients and treatment characteristics of these
forms the basis of this report. In addition, we provide systemic
review of the treatment of PRCA following allogeneic transplant
from the published literature. Results: All 3-patients had acute
myelogenous leukemia and received graft from ABO incompatible
donor. The median age was 49 years (range  39–62). Condition-
ing and GVHD prophylaxis included, CY/TBI 2, BU/CY1,
Cyclosporine  Methotrexate  3. Median time to PRCA from
the date of transplant was 30 weeks (range 13–32). Two patients
received treatment with prednisone at 1 mg/kg; one patient was
treated with Erythropoietin alone. Median time to respond and
transfusion independence in steroid treated patients was 15 days
(data not available for patient treated with Erythropoietin). Total
of 39 published reports describe 60 patients with PRCA following
ABO mismatch allogeneic transplant. The successful treatment of
PRCA varies widely and include, no treatment (spontaneous res-
olution)  15, Cyclosporine discontinuation 4, tapering of cy-
closporine and onset of GVHD  2, reinstitution of cyclospor-
ine  1, Erythropoietin alone  7, Steroids alone  4, Steroids 
Erythropoietin  1, Plasmapheresis  10, Immuno-adsorption
aphaeresis  4, Antilymphocyte globulin  2, Antithymocyte
globulin 2, Rituximab 2, Donor leukocyte infusion (DLI) 2.
Treatment details were not available in 4 reports. The median time
to response (transfusion independence) is available in 19/60 pa-
tients. Median time to response was higher in patients with DLI
and immunotherapy (observation/erythropoietin/steroids/CSA ta-
pering 56 days, ATG/ALG/Rituximab/DLI 69).Conclusion:
Initial management with observation, cyclosporine tapering, eryth-
ropoietin with or without steroids results in resolution of PRCA in
over 50% patients. Refractory patients should be treated with
plasmapheresis, immuno-adsorption aphaeresis, immunotherapy
(ATG, ALG, Rituximab, DLI) in that order.
111
PROGNOSTIC FACTORS FOR ALLOGENEIC STEM CELL TRANSPLANTA-
TION (ASCT) FOR UNTREATED FIRST RELAPSE OF ACUTE MYELOID
LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Alamo, J.G.; Shahjahan, M.; Wong, R.S.; de Lima, M.; Khouri, I.;
Gajewski, J.; Couriel, D.; Andersson, B.S.; Anderlini, P.; Champlin, R.;
Giralt, S. University of Texas M.D. Anderson Cancer Center, Houston,
TX.
Introduction: The treatment of patients relapsing after primary
therapy for Acute Myeloid Leukemia or High Risk Myelodysplas-
tic Syndromes is controversial. Although many centers recommend
proceeding to allografting if a donor is available without re-induc-
tion therapy, the data on which this recommendation is based is
limited, because of small numbers and patient heterogeneity.
Methods: To determine potential clinical factors that could allow
physicians to decide which patients with ﬁrst relapse AML/MDS
could beneﬁt or not from re-induction therapy we performed a
retrospective analysis of 81 patients (39 males; 42 females) who
received ASCT for untreated AML after First Relapse (n60),
MDS (n13) and MDS/AML (n8) between 01/1989 and 02/
2003 at M.D. Anderson Cancer Center. Results: Median age was
39 years (range 17–68). The median time interval from diagnosis
to transplant was 0.7 years (range 0.22–4.23). 73 patients received
transplant from related donors (63 siblings, 5 children, 5 parents)
and 8 from matched unrelated donors. Preparative regimens in-
cluded TBI based (n20), FM	 ATG (n10), FB	 ATG, Bu/Cy
(n11), Bu/Cy/TT (n18), BuCyDAC (n2), others (n8).
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Graft-versus-host-disease (GvHD) prophylaxis included Tacroli-
mus based (n52), Cyclosporine based (n27) and other regimens
(n2). 37 patients received PBPC and 44 received BM transplant.
The overall survival (OS), disease free survival (DFS) and non-
relapse mortality (NRM) at 1 year were 38%, 31%, and 32%
respectively. Results of the univariate analysis for various potential
prognosis factors are shown in the Table. First CR of more than 1
year and performance status of 0 at transplantation were predictors
of better OS, and DFS at 1 year. Conclusion: In patients with
untreated First Relapse AML/MDS, longer duration of ﬁrst CR
and better performance status were predictors of better outcomes
of allogeneic HSCT in this patient population. These patients
could be considered for allogeneic HSCT upon their ﬁrst relapses.
Development of better treatment strategies may help to improve
outcomes in other patients without these good prognostic factors.














AML 33% 25% 30%
MDS 29% NS 21% NS 48% NS
AML/MDS 43% NS 43% NS 33% NS
Duration of first CR
>1 year 66% 61% 16%
Duration of first CR
<1 year 30% 0.01 26% 0.003 25% 0.9
Absence of PB blast
at relapse 45% 38% 31%
Presence of PB blast
at relapse 37% NS 35% NS 25% NS
BM Leukemic
Infiltrate <10% 32% 25% 33%
BM Leukemic
Infiltrate >10% 52% NS 40% NS 18% NS
Poor risk cytogenetic
results at relapse 34% 24% 37%
Other cytogenetic
results at relapse 41% NS 40% NS 25% NS
Performance status 0
at transplant 46% 46% 16%
Performance status
>0 at transplant 32% 0.02 25% 0.01 31% 0.1
*By log rank test, NS indicates not signiﬁcant.
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DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE DEPENDS UPON
ESTABLISHMENT OF COMPLETE DONOR T CELL CHIMERISM AFTER T
CELL DEPLETED, REDUCED INTENSITY HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Hardy, N.M.1; Steinberg, S.M.2; Krumlauf, M.1; Cvitkovic, R.3; Cas-
tro, K.1; Hakim, F.1; Carter, C.4; Read, E.J.4; Leitman, S.4; Gress, R.1;
Bishop, M.R.1 1. National Institutes of Health/National Cancer Insti-
tute/Experimental Transplantation and Immunology Branch, Bethesda,
MD; 2. National Institutes of Health/National Cancer Institute/Biosta-
tistics and Data Management Section, Bethesda, MD; 3. Brigham
Young University, Provo, UT; 4. National Institutes of Health/Clinical
Center/Department of Transfusion Medicine, Bethesda, MD.
Introduction: As part of a protocol to study the inﬂuence of host
immunodepletion on engraftment, in which we administered DLI
after TCD-RIST, we were able to analyze the effect of donor
engraftment on the development of GVHD. Methods: Eighteen
patients with metastatic breast cancer were enrolled. Each received
1–2 cycles of cyclophosphamide (600 mg/m2/day) and ﬂudarabine
(30 mg/m2/day) for four days, to a target CD4 count of 50 cells/l.
Pts then received ﬂudarabine (30 mg/m2/day) and cyclophospha-
mide (1200 mg/m2/day) from day 6 to 3 prior to matched
sibling donor allotransplantation. The allografts were TCD by
sequential CD34 positive-selection and negative selection using
monoclonal antibodies against CD2, CD6, and CD7, with T cell
add-back to an adjusted dose 1  105 CD3 cells/kg. Pts received
a minimum of 5  106 CD34 cells/kg. Pts received full dose
cyclosporine A (CsA) until day 28 followed by tapering over
twelve days. Pts without GVHD received 1, 5, and 10 106 CD3
cells/kg on days 42, 70, 98, respectively. Pts were eligible to
receive additional DLI beyond day 98. Results: Two pts died
before day 28 and were not included in the analysis. All remaining
pts achieved complete donor T cell engraftment upon completion
of scheduled DLI. Nine pts (56%) developed grade II-IV acute
GVHD. Four of 14 evaluable pts (29%) developed chronic
GVHD, two extensive. Development of GVHD was associated
with complete (90%) donor T cell chimerism (p
.005); only one
patient with mixed T cell chimerism developed GVHD. There was
no association between the absolute lymphocyte count and either
GVHD or establishment of chimerism. Three of 16 pts (19%) did
not receive DLI due to GVHD. Five of 16 pts (31%) received one
or two of three planned DLI. Six received more than three DLI,
for disease control. There was no correlation between the number
or dose of DLI administered and the development of GVHD.
Conclusions: In marked contrast to reports of non-myeloablative
HST, we found a strong association between complete donor T
cell engraftment and the development of GVHD following RIST,
suggesting a suppressive effect of recipient T cells. This could be
from direct cytotoxicity or the activity of a regulatory subset,
controlling alloreactivity until full donor chimerism is established.
While lower rates of GVHD following RIST have been reported,
T cell chimerism may be confounding.
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ESTABLISHMENT OF A NATIONAL CORD BLOOD BANKING NETWORK
THROUGH THE NATIONAL MARROW DONOR PROGRAM
Kurtzberg, J.1; Creer, M.2; Halet, M.3; Welte, K.3; Boo, M.3; Confer,
D.3; Chell, J.3, for the members of the NMDP Cord Blood Banking
Network. 1. Duke University Medical Center, Durham, NC; 2. St.
Louis Cord Blood Bank, St. Louis, MO; 3. National Marrow Donor
Program, Minneapolis, MN.
The majority of patients in need of a bone marrow or stem cell
transplant do not have a matched related family member to serve as
their donor. Over 17 years ago, the National Marrow Donor
Program was established to provide a registry of volunteer adult
unrelated donors for patients in need of a hematopoietic stem cell
transplant. The NMDP lists 5,000,000 adult donors and has
facilitated 20,000 transplants to date. Despite this success, ap-
proximately 30% of Caucasian and 80% of African American and
Asian patients are unable to ﬁnd a suitably matched adult volunteer
donor. Over the past 11 years, studies have demonstrated that
banked unrelated donor, partially HLA mismatched umbilical cord
blood (UCB) could serve as an alternative source of hematopoietic
stem and progenitor cells for allogeneic transplantation. UCB may
increase access to transplantation therapy for patients lacking a
matched donor, particularly those of ethnic or racial minority
backgrounds. To date, approximately 14 public cord blood banks
have been established in the U.S. creating a heterogeneous inven-
tory of approximately 50,000 cord blood units (CBUs). Uniform
standards were not followed by the different banks and all lack
sufﬁcient inventory of HLA diverse, large CBUs. Over the past
year, 13 U.S. banks have voluntarily joined together to create a
network of public cord blood banks as part of the NMDP. A
steering committee was established comprised of cord blood bank
directors, transplanters, experts in HLA, an ethicist, representation
from FDA and HRSA with experts in information technology (IT)
and administrative support from the NMDP. The committee
adopted uniform standards for cord blood donor recruitment and
screening, donor education and consent, medical histories, infec-
tious disease and hemoglobinopathy testing, cord blood collection,
processing, testing, cryopreservation and storage. Subcommittees
for quality standards, collection, education, research, IT, econo-
mies, bank/transplant center interface and proﬁciency testing were
developed with active ongoing agendas. Management systems for
UCB donor searches, collection, analysis and distribution of clin-
ical outcomes data back to the banks are being established. This
NMDP Cord Blood Banking Network represents the ﬁrst coop-
erative effort unifying the majority of public cord blood banks in
the U.S. Importantly, all CBUs will be listed on a single web-based
search registry providing easy access to all NMDP Transplant
Centers.
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